Search Results

RANOLAVIB 500 ER #

RANOLAZINE 500mg. IP

Send Enquiry

CURE

Tablets

Packaging and packing Type

Blister | 10x10

MRP :

₹168

PTR :

₹120

PTS :

₹108

Belongs to a class of drugs called antianginal agents that are used in the treatment of chronic stable angina pectoris. (David T Nash, 2008) An antia... Read More

Composition

RANOLAZINE 500mg. IP

Send Enquiry

India’s Largest Pharma Franchise

100%

Genuine Products

Secure

Payments

24 x 7

Customer Support

About the product

Description

Belongs to a class of drugs called antianginal agents that are used in the treatment of chronic stable angina pectoris. (David T Nash, 2008) An antianginal agent that relieves ischemia by reducing myocardial cellular sodium and calcium overload via inhibition of the late sodium current of the cardiac action potential. (Benjamin M Scirica, 2007) Offers clinicians a new option in the long-term treatment of patients with angina. (Benjamin M Scirica, 2007) A beneficial option for patients with chronic stable angina whose symptoms are not controlled with first-line antianginal therapy or who do not tolerate first-line antianginal agents. (Keating, 2008) A potent anti-anginal agent capable of producing anti-ischemic effects without reducing heart rate or blood pressure. (Charles Antzelevitch, 2004) A selective inhibitor of the late sodium current in myocytes with anti-ischemic and metabolic properties. (J Nicolás Codolosa, 2014) A cost-effective drug due to its ability to decrease angina-related hospitalizations and improve quality of life. (J Nicolás Codolosa, 2014) A promising therapeutic drug for patients who have chronic stable angina that failed conventional antianginal medications. (Bălan, 2010) Improves functional capacity and decreases anginal episodes in chronic stable angina patients. (J Nicolás Codolosa, 2014) A potent antianginal agent that, unlike beta-blockers, nitrates, or calcium channel blockers, does not affect either heart rate or blood pressure. (Wenger, 2010) Controls angina symptoms and improves exercise tolerance in patients with coronary heart disease. (Wenger, 2010) A good therapeutic choice for patients with chronic stable angina. (Andrea Rognoni, 2013) A valuable addition to the treatment of chronic stable angina with an excellent safety profile. (Ole Ahlehoff, 2009) Significantly reduces the frequency of anginal attacks and the need for use of short-acting nitroglycerine. (Thorsten Reffelmann, 2010) A safe and effective option for monotherapy or add-on therapy to reduce anginal symptoms in patients with chronic stable angina. (Robert A Kloner, 2013)

Side Effects

Dizziness, Headache, Nausea, Tiredness, Constipation

Indication

Chronic angina

Important Notice

Temp data

Storage Condition

Product details for storage condition Product details for storage condition Product details for storage condition Product details for storage condition

Similar Products

No products found.

Looking into the future of healthcare

Contact

Plot No 4, HSIIDC IT PARK, Sector 22,Panchkula, Haryana, India 134109

Phone: 9888988858

Business Hours

Mon-Sat: 9AM to 6PM

Franchise Enquiry

Request a callback to get more information about becoming a PCD Franchise Owner***

    Send Enquiry

    Request a callback to get more information about becoming a PCD Franchise Owner